Addisu, Ayenew; Adriaensen, Wim; Balew, Arega; Asfaw, Mekuria; Diro, Ermiyas; Garba Djirmay, Amadou; Gebree, Desalegn; Seid, Getahun; Begashaw, Hailemariam; Harries, Anthony D; +25 more... Hirpa Adugna, Abera; Ayalew Jejaw, Zeleke; Kamau, Edward Mberu; Kelbo, Tigist; Manzi, Marcel; Medebo Daniel, Dana; Moloo, Ashok; Olliaro, Piero; Owiti, Philip; Reeder, John C; Senkoro, Mbazi; Takarinda, Kuda; Terry, Robert; Timire, Collins; Tucho, Samson; Tweya, Hannock; Wendemagegn, Yeshanehe; Verdonek, Kristien; Vogt, Florian; van Henten, Saskia; van Griensven, Johan; Worku, Bekele; Zolfo, Maria; Zachariah, Rony; Ethiopia SORT IT Neglected Tropical Diseases Group; (2019) Neglected tropical diseases and the sustainable development goals: an urgent call for action from the front line. BMJ global health, 4 (1). e001334-. ISSN 2059-7908 DOI: https://doi.org/10.1136/bmjgh-2018-001334

Downloaded from: http://researchonline.lshtm.ac.uk/4652846/

DOI: https://doi.org/10.1136/bmjgh-2018-001334

Usage Guidelines:

Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: Creative Commons Attribution Non-commercial http://creativecommons.org/licenses/by-nc/3.0/
Neglected tropical diseases and the sustainable development goals: an urgent call for action from the front line

Ayenew Addisu,1 Wim Adriaensen,2 Arega Balew,3 Mekuria Asfaw,4 Ermias Diro,5 Amadou Garba Djirmay,6 Desalegn Gebree,7 Getahun Seid,8 Hailemariam Begashaw,9 Anthony D Harries,10,11 Abera Hirpa Adugna,7 Zeleke Ayalew Jejaw,1 Edward Mberu Kamau,12 Tigist Kelbo,4 Marcel Manzi,13 Dana Medebo Daniel,14 Ashok Moloo,6 Piero Olliaro,2,12 Philip Owiti,12 John C Reeder,12 Mbazi Senkoro,16 Kuda Takarinda,17 Robert Terry,18 Collins Timire,17 Samson Tucho,19 Hannock Tweya,20 Yeshanehe Wendemagine,21 Kristien Verdonck,2 Florian Vogt,2 Saskia van Henten,2 Johan van Griensven,22 Bekele Worku,23 Maria Zolfo,2 Rony Zachariah,12 Ethiopia SORT IT Neglected Tropical Diseases Group

“We must become bigger than we have been: more courageous, greater in spirit, larger in outlook.”

Emperor Haile Selassie

It was in the city of Gondar in Ethiopia, one of the highest burden countries for neglected tropical diseases (NTDs)1 and currently home to 16 to 20 recognised NTDs (table 1), that a unanimous desire was expressed by scientists, policy makers and health workers from around the world (the forum was an operational research training on NTDs organised by the Structured Operational Research and Training Initiative (SORT IT). SORT IT is a global partnership coordinated by the Special Programme for Research and Training in Tropical Diseases (TDR) hosted at the WHO. http://www.who.int/tdr/capacity/strengthening/sort/en/, for urgent reflection on how to garner support and hasten the pace towards achieving the fast approaching Sustainable Development Goal (SDG) target of eliminating NTDs by 2030.2 Concerns, raised by the group are articulated below:

First, there is the term ‘Neglected Tropical Diseases’, coined by Peter Hotez and colleagues in 2003 with the noble intention of propelling political momentum, catalysing donor funding and making quantum shifts in research and development (R&D).3 The question today is whether designating a specific group of diseases as being ‘neglected’ does not carry with it a negative and disempowering connotation. Populations affected by NTDs already face neglect by being the world’s poorest and facing social stigmatisation, prejudice and marginalisation. Lacking a ‘strong political voice’, these communities have a low profile and status in public health priorities.4 Having the label of ‘neglected’ added to their illnesses may accentuate their predicament. Put simply, how can human beings, who risk being diminished by being designated as ‘neglected’ by us in the health system, be considered equal partners in their own care? Language is more than words: it has the power to transform the way people think and behave.5

This term may thus allow politicians and donors to maintain a ‘business-as-usual’ mode by accepting the idea of neglect as an unchangeable paradigm, dampening the drivers behind political impetus and funding. The quote from a SORT IT
urgently needed. HIV/AIDS is a good example. The but strong activism and political momentum is now passiveness. tive for continued funding support it may encourage criteria for getting on or off the list. Furthermore, since needed to eliminate NTDs, including clear objective reflecting the mind-set change that is urgently needed. eering designation with an imperative for action which ‘Tropical diseases needing special attention’- an empow- tinal worms, but I was quickly dissuaded by many in academic ‘I hoped to do my PhD on intesti- nal worms, but I was quickly dissuaded by many in academic and government circles saying it is a neglected disease’. The Amharic (Ethiopian) translation of NTDs reads ‘Tropical diseases needing special attention’- an empowering designation with an imperative for action which reflects the mind-set change that is urgently needed. Second, the 15 years of naming this constellation of diseases of poverty as ‘Neglected Tropical Diseases’ have not really changed the paradigm, as we have only kept adding to the list of NTDs with none coming off permanently. This is proof that much more is needed to eliminate NTDs, including clear objective criteria for getting on or off the list. Furthermore, since being removed from the NTD list may be a disincentive for continued funding support it may encourage passiveness. Bringing NTDs into the SDG agenda is laudable, but strong activism and political momentum is now urgently needed. HIV/AIDS is a good example. The ‘3 by 5’ initiative, launched by the Joint United Nations Programme on HIV/AIDS (UNAIDS) and WHO in 2003, was a global target to provide life-prolonging antiretroviral treatment (ART) to three million people living with HIV/AIDS in low-income and middle-income countries by the end of 2005. This was followed by Universal Access targets, the Treatment 2.0 Strategy and the UNAIDS 90-90-90 treatment targets. All of these were important drivers that simplified therapy, increased treatment coverage and crystallised the necessary environment for the establishment of operational and programmatic components for an expanded and sustainable global response to HIV/AIDS. From hundreds on ART in 2003, the result was 21.7 million on ART by 2017. Such initiatives reached fruition because of a public health approach to ART scale-up as part of Universal Health Coverage (UHC). It is time to gear similar political and funding impetus towards NTDs. Since the NTD package includes a diversity of diseases, the role of disaggregated or appropriately combined treatment targets may help. Third, the list of NTDs is diverse, with parasitic, bacterial, viral, fungal infections and snakebite envenoming. Unlike diseases such as HIV/AIDS, TB and Malaria, there are practical difficulties in building strong communities of practice, as NTD work is often confined to silos of specific diseases. While recognising the specificities of each condition, new ways of building an integrated approach that compels stake holders to look beyond ‘the trees to see the forest’ are needed. The WHO Roadmap strategy on control, elimination and eradication of NTDs is commendable, but it is geared only until 2020 and urgent work is needed to align it with the 2030 SDG target. Importantly, the road map is largely focused on the diseases for which medicines and large-scale prevention and treatment options exist, such as for onchocerciasis, lymphatic filariasis, schistosomiasis, soil-transmitted helminths (STH) and trachoma. Implementation of large-scale prevention and treatment is often hampered by shortages of drugs and vaccines which needs to be addressed. Vector control activities are also required for vectorborne diseases, such as dengue and leishmaniasis, while veterinary public health as part of the ‘One Health’ approach is needed for zoonotic diseases, such as taeniasis/neuro-cystercerosis, echinococcosis and rabies. The provision of safe water, sanitation and hygiene (WASH) is another key component of the WHO strategy to overcome NTDs such as trachoma and STH. These interventions, and how they are integrated into broader health systems and within the principles of UHC, are spelt out in the WHO’s 4th comprehensive Report on NTDs, but in contrast to tuberculosis and HIV/AIDS, this lacks clear and measurable targets and milestones by which to judge progress. If we are to eliminate NTDs by, 2030 the ‘how to’ of this gigantic task needs to be defined including milestones and targets.

Finally, there is an urgent need for a quantum shift in funding for R&D and for treatment access. Despite evidence that interventions to address NTDs are one of the best health investments, only 0.6% of development assistance for health is allocated to NTDs that affect about 1.5 billion people or roughly 20% of the

<table>
<thead>
<tr>
<th>Category</th>
<th>Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protozoan infections</td>
<td>1. Chagas disease</td>
</tr>
<tr>
<td></td>
<td>2. Human African trypanosomiasan</td>
</tr>
<tr>
<td></td>
<td>3. Leishmaniasis</td>
</tr>
<tr>
<td>Helminth infections</td>
<td>4. Taenia solium (neuro) cysticercosis/ Taeniosis</td>
</tr>
<tr>
<td></td>
<td>5. Dracunculiasis</td>
</tr>
<tr>
<td></td>
<td>6. Echinococcus</td>
</tr>
<tr>
<td></td>
<td>7. Foodborne trematodiasiens</td>
</tr>
<tr>
<td></td>
<td>8. Lymphatic filariasis</td>
</tr>
<tr>
<td></td>
<td>9. Onchocerciasis</td>
</tr>
<tr>
<td></td>
<td>10. Schistosomiasis</td>
</tr>
<tr>
<td></td>
<td>11. Soil-transmitted helminthias (ascariasis, Hookworm diseases, trichuriasis, strongylaidiasis)</td>
</tr>
<tr>
<td>Bacterial infections</td>
<td>12. Buruli ulcer</td>
</tr>
<tr>
<td></td>
<td>13. Leprosy</td>
</tr>
<tr>
<td></td>
<td>14. Trachoma</td>
</tr>
<tr>
<td></td>
<td>15. Yaws</td>
</tr>
<tr>
<td>Viral infections</td>
<td>16. Dengue and chikungunya fevers</td>
</tr>
<tr>
<td></td>
<td>17. Rabies</td>
</tr>
<tr>
<td>Fungal Infections</td>
<td>18. Mycetoma, chromoblastomycosis, deep mycosis</td>
</tr>
<tr>
<td>Ectoparasitic infections</td>
<td>19. Scabies, Myiasis</td>
</tr>
<tr>
<td>Venom</td>
<td>20. Snakebite envenoming</td>
</tr>
</tbody>
</table>

Figure 1  Impact of market on product pipeline (diagnostics, drugs vaccines) starting from the preclinical stage for various diseases. Type II diseases: are incident in both rich and poor countries with substantial proportion of the cases in poor countries. Type III disease: are those that are overwhelmingly or exclusively incident in developing countries. NTDs, neglected tropical diseases.

This is clear evidence of inequity in global health financing which needs correction. In 2015, WHO estimated that US$18 billion (US$3.6 billion a year) was the investment target to achieve the NTD road map until 2020. The reality lies at less than US$ 200 million a year - a 94% yearly shortfall.

Similarly, there is an inverse relationship between commercial market size and products in the R&D pipeline. NTDs lie towards the bottom of the pile (Figure 1). A 2018 TDR publication drew attention to the fact that the current R&D pipeline is dominated by three diseases—malaria, HIV/AIDS and tuberculosis. For NTDs, 12 (57%) of 20 NTDs have nothing at all in the pipeline (Figure 2). This finding reiterates the need to establish a new funding model for NTD-related R&D and the need for national and regional investments. Africa is the continent most affected by the NTD burden, but contributes less than 1% to global expenditure on R&D. The BRICS (Brazil, Russia, India, China and South Africa) and G20 countries have an opportunity to show leadership in addressing this challenge. A possible way forward is to call on G20 countries to generate a special fund for NTDs since the NTD burden is highest among the poor in G20 countries (together with Nigeria) and they have capacity to develop generic products. Furthermore, NTDs are pervasive wherever poverty and vulnerable populations exist, including emerging market economies. If these countries would effectively implement NTD programmes, a large proportion of the NTD burden would be resolved. NTD endemic populations are the least likely to be able to meet SDG targets that include UHC (target 3.8), safe water (target 6.1) and sanitation (target 6.2) and as such they can serve as tracers of equity in progress towards the SDGs.

Reflection on how existing global funding mechanisms such as the Global Fund Against AIDS, TB and Malaria (GFATM) could also embrace NTDs as part of their portfolio is needed more than ever before. From an operational perspective, this seems logical as areas endemic for NTDs also tend to be endemic for HIV/AIDS, tuberculosis and malaria. Coinfections with STH and schistosomiasis are also known to exacerbate the progression of the aforementioned diseases. A promising way of pushing the NTD agenda and leveraging political attention and resources would thus be an integrated management approach to NTDs, Malaria, Tuberculosis and HIV and a call for public health action at a broad level in countries. Such an approach would also strengthen the general health
system with benefits to the management and control of NTDs.

When new drugs are developed for NTDs, they need to be deployed at programmatic level as quickly as possible, and here the funding support from GFATM for operational research would facilitate a win-win situation. Whatever the eventual choice may be, articulating the mechanisms for funding remains a glaring gap.

In conclusion, in countries like Ethiopia how well we do with NTDs could serve as 'tracers of equity' towards the SDGs and markers of the philosophy of 'leaving none behind'. We must succeed, but that will depend on the backing of a supportive political environment, coupled with new science, funding (particularly by G20 countries) and robust advocacy. Most of all, we will need a greatly strengthened sense of global solidarity focused on the needs of the poorest and most vulnerable and with the participation of all countries, all stakeholders and all people.1 If we are to transform the NTD world for the SDGs, it will require us to first transform our thinking and actions.

Author affiliations
1Medical parasitology and internal medicine, University of Gondar, Gondar, Ethiopia
2Tropical Diseases, Institute of Tropical Medicine, Antwerp, Belgium
3Internal medicine, Yekatit 12 Hospital Medical College, Addis Ababa, Ethiopia
4Research and training, Arba Minch University, Arba Minch, Ethiopia
5Internal Medicine, University of Gondar, Gondar, Ethiopia
6Neglected Tropical Diseases, World Health Organisation, Geneva, Switzerland
7Malaria, neglected tropical and zoonotic diseases, Ethiopian Public Health Institute, Addis Ababa, Ethiopia
8Boru Meda Hospital, Amhara Regional Health Bureau, Amhara, Ethiopia
9Health programme, The Jimmy Carter Center, Addis Abeba, Ethiopia
10Center for Operational Research, International Union Against TB and Lung Disease, Paris, France
11Tropical medicine, London School of Hygiene and Tropical Medicine, London, UK
12Research for implementation, Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
13Operational research (LUXOR), Médecins Sans Frontieres (LuxOR), Luxembourg City, Luxembourg
14Institute of health, Jimma University, Jimma, Ethiopia
15Center for operational research, International Union Against TB and Lung Disease, Nairobi, Kenya
16Medical research, National Institute for Medical Research, Dar es Salaam, Tanzania
17Center for operational research, International Union Against TB and Lung Disease, Harare, Zimbabwe
18Research Policy, Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
19Clinical monitoring, KalaCORE Program, Amigos Da Silva, Addis Abeba, Ethiopia
20Monitoring and evaluation, Light House Trust, Paris, France
21Dermatology and Veneriology, Bahar Dar University, Bahir Dar, Ethiopia
22Clinical Sciences, Instituut voor Tropische Geneeskunde, Antwerpen, Belgium
23Malaria and neglected tropical diseases, World Health Organisation Country Office, Addis Abeba, Ethiopia

Contributors RZ wrote the first draft of the manuscript which was reviewed by all authors who significantly contributed to the content and approved the final version.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Disclaimer The views expressed in this article are those of the authors and may not necessarily reflect those of their affiliated institutions.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Data sharing statement All data from this article have already been published and available in the public domain.
REFERENCES